Shire Pharmaceuticals Group Plc
Shire Receives Extension of Market Authorization in Europe for Revestive (Teduglutide) for the Treatment of Paediatric Patients with Short Bowel Syndrome (SBS)
Zug, Switzerland (ots/PRNewswire) - This press release is intended for a global audience. First therapy indicated in the EU for use in patients aged one year and above with SBS, a rare gastrointestinal condition Shire (LSE: SHP, NASDAQ: SHPG) today announced that the European Commission has granted extension of ...